PortalPublikationenRapidly progressive and metastatic mucoepidermoid carcinoma:...

Rapidly progressive and metastatic mucoepidermoid carcinoma: application of serological tumor markers.

Standard

Rapidly progressive and metastatic mucoepidermoid carcinoma: application of serological tumor markers. / Friedrich, Reinhard; Klapdor, Rainer; Bartel-Friedrich, Sylva.

in: ANTICANCER RES, Jahrgang 27, Nr. 4, 4, 2007, S. 2099-2100.

Publikationen: SCORING: Beitrag in Fachzeitschrift/Zeitung › SCORING: Zeitschriftenaufsatz › Forschung › Begutachtung

Harvard

Friedrich, R, Klapdor, R & Bartel-Friedrich, S 2007, 'Rapidly progressive and metastatic mucoepidermoid carcinoma: application of serological tumor markers.', ANTICANCER RES, Jg. 27, Nr. 4, 4, S. 2099-2100. <http://www.ncbi.nlm.nih.gov/pubmed/17649828?dopt=Citation>

APA

Friedrich, R., Klapdor, R., & Bartel-Friedrich, S. (2007). Rapidly progressive and metastatic mucoepidermoid carcinoma: application of serological tumor markers. ANTICANCER RES, 27(4), 2099-2100. [4]. http://www.ncbi.nlm.nih.gov/pubmed/17649828?dopt=Citation

Vancouver

Friedrich R, Klapdor R, Bartel-Friedrich S. Rapidly progressive and metastatic mucoepidermoid carcinoma: application of serological tumor markers. ANTICANCER RES. 2007;27(4):2099-2100. 4.

Bibtex

@article{4aff3246ea9f4e5190ec4443cb40aad2,
title = "Rapidly progressive and metastatic mucoepidermoid carcinoma: application of serological tumor markers.",
abstract = "Mucoepidermoid carcinoma (MEC) of the salivary gland is a rare entity. A distinction of 2 variants has been proposed: the low-grade tumor with a favourable prognosis and the high-grade tumor with a poor prognosis. Indeed, MEC is a cancer with a relative favourable outcome and more than 90% of patients survive for more than 5 years after diagnosis, reduced to about 70% after 10 years. This excellent prognosis might contribute to the unacceptable retention of the term {"}mucoepidermoid tumor{"} in the medical terminology, even in current medical textbooks. However, the distinction of MEC by grading is a guideline only and it is not appropriate to use this histological term as a prediction for individual cases. We describe the rapid fatal outcome of a patient with MEC in order to emphasize the malignant characteristics of this tumor and the possible application of tumor markers for the diagnosis of metastasizing MEC.",
keywords = "Bone Neoplasms, Carcinoma, Mucoepidermoid, Disease Progression, Fatal Outcome, Humans, Liver Neoplasms, Lung Neoplasms, Male, Middle Aged, Salivary Gland Neoplasms, Salivary Glands, Minor, Tumor Markers, Biological",
author = "Reinhard Friedrich and Rainer Klapdor and Sylva Bartel-Friedrich",
year = "2007",
language = "English",
volume = "27",
pages = "2099--2100",
journal = "ANTICANCER RES",
issn = "0250-7005",
publisher = "International Institute of Anticancer Research",
number = "4",

}

RIS

TY - JOUR

T1 - Rapidly progressive and metastatic mucoepidermoid carcinoma: application of serological tumor markers.

AU - Friedrich, Reinhard

AU - Klapdor, Rainer

AU - Bartel-Friedrich, Sylva

PY - 2007

Y1 - 2007

N2 - Mucoepidermoid carcinoma (MEC) of the salivary gland is a rare entity. A distinction of 2 variants has been proposed: the low-grade tumor with a favourable prognosis and the high-grade tumor with a poor prognosis. Indeed, MEC is a cancer with a relative favourable outcome and more than 90% of patients survive for more than 5 years after diagnosis, reduced to about 70% after 10 years. This excellent prognosis might contribute to the unacceptable retention of the term "mucoepidermoid tumor" in the medical terminology, even in current medical textbooks. However, the distinction of MEC by grading is a guideline only and it is not appropriate to use this histological term as a prediction for individual cases. We describe the rapid fatal outcome of a patient with MEC in order to emphasize the malignant characteristics of this tumor and the possible application of tumor markers for the diagnosis of metastasizing MEC.

AB - Mucoepidermoid carcinoma (MEC) of the salivary gland is a rare entity. A distinction of 2 variants has been proposed: the low-grade tumor with a favourable prognosis and the high-grade tumor with a poor prognosis. Indeed, MEC is a cancer with a relative favourable outcome and more than 90% of patients survive for more than 5 years after diagnosis, reduced to about 70% after 10 years. This excellent prognosis might contribute to the unacceptable retention of the term "mucoepidermoid tumor" in the medical terminology, even in current medical textbooks. However, the distinction of MEC by grading is a guideline only and it is not appropriate to use this histological term as a prediction for individual cases. We describe the rapid fatal outcome of a patient with MEC in order to emphasize the malignant characteristics of this tumor and the possible application of tumor markers for the diagnosis of metastasizing MEC.

KW - Bone Neoplasms

KW - Carcinoma, Mucoepidermoid

KW - Disease Progression

KW - Fatal Outcome

KW - Humans

KW - Liver Neoplasms

KW - Lung Neoplasms

KW - Male

KW - Middle Aged

KW - Salivary Gland Neoplasms

KW - Salivary Glands, Minor

KW - Tumor Markers, Biological

M3 - SCORING: Journal article

C2 - 17649828

VL - 27

SP - 2099

EP - 2100

JO - ANTICANCER RES

JF - ANTICANCER RES

SN - 0250-7005

IS - 4

M1 - 4

ER -